Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Contact Us

To learn more about Avalanche and our therapies for treating eye-related diseases, contact us.

Avalanche Biotechnologies
1035 O’Brien Drive, Suite A
Menlo Park, CA 94025

Tel: 650-272-6269
Fax: 650-276-7166

Email:

General Inquiry: info@avalanchebiotech.com
Careers: careers@avalanchebiotech.com
Business Development: busdev@avalanchebiotech.com

Or Submit This Contact Form:

Send To:
First Name:*
Last Name:*
Title:
Company Name:*
E-mail Address:*
Phone Number:
Message:*
 

The results of a Phase 1, 52-week trial of Avalanche Biotechnologies’ rAAV.sFLT-1 (AVA-101) gene therapy for the treatment of wet age-related macular degeneration (wAMD) have been published online by The Lancet. The study sought to evaluate the safety of rAAV.sFLT-1 via a single subretinal injection. Results of the study demonstrate that rAAV.sFLT-1 was safe and well tolerated, and support ocular gene therapy as a potential long-term treatment option for wAMD.

“The use of gene therapy to reprogramme genetically normal cells of the retina to take on additional functions opens a new chapter in potential AAV applications.”
– Dr. Robert MacLaren, Moorsfield Eye Hospital

The complete article and editorial commentary by Dr. MacLaren, are available from The Lancet.

Read All Avalanche News

@Avalanchebio Twitter Feed

Connect with Avalanche Biotech on Twitter